Circulation

OCTOBER 20, 2024

Circulation, Volume 150, Issue 17 , Page 1313-1314, October 22, 2024.

Heart Transplant 45

Heart Transplant Transplant Circulation 45

Cardiology Update

APRIL 25, 2024

RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heart failure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. April 6, 2024.

Heart Failure 98

Heart Failure Heart Transplant Transplant Research 98

DAIC

FEBRUARY 21, 2024

Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices. For three consecutive years, U.S.

Pediatrics 105

Pediatrics Hospital Heart Failure Transplant 105

Circulation

MAY 19, 2024

Circulation, Volume 149, Issue 21 , Page 1667-1669, May 21, 2024.

Heart Transplant 53

Heart Transplant Transplant Circulation 53

DAIC

APRIL 30, 2024

Study shows that cardiac spheroids, derived from human induced pluripotent stem cells, can be easily transported and injected into damaged areas of the heart to promote its regeneration and recovery of function. Heart attacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state.

Transplant 105

Transplant Heart Transplant Myocardial Infarction Heart attacks 105

Cardiology Update

JANUARY 22, 2024

The primary outcome was death from any cause, and the secondary outcome included a composite of death, heart transplantation, or ventricular assist device implantation. At a mean (±SD) follow-up of 40±20 months, CRT showed a significantly lower risk of death or hospitalization due to heart failure.

Heart Failure 115

Heart Failure Defibrillator Heart Transplant Transplant 115

DAIC

APRIL 16, 2024

milla1cf Tue, 04/16/2024 - 12:35 April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. See more details at TCTMD.

Heart Failure 104

Heart Failure Quality of Life Transplant Heart Transplant 104

DAIC

FEBRUARY 22, 2024

The inherited heart condition often goes undiagnosed until it advances to heart failure, which is why it’s important to identify those at risk and begin treatment early. heart failure/heart transplant programs that contributed to the study.

Heart Failure 104

Heart Failure Sudden Cardiac Death Heart Transplant Cardiomyopathy 104

The American Journal of Cardiology

JULY 24, 2024

Publication date: Available online 23 July 2024 Source: The American Journal of Cardiology Author(s): Giulio Cacioli, Michele Ciabatti, Ernesto Cristiano, Claudia Notari, Ilaria Papisca, Giada Distefano, Giovanni Menafra, Paola Lilla Della Monica, Mariano Antonio Feccia, Amedeo Pergolini, Viviana Maestrini, Fabio Sbaraglia, Federico Ranocchi, Francesco (..)

Heart Transplant 52

Heart Transplant Transplant 52

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146828-A4146828, November 12, 2024. Heart transplantation remains a vital treatment for end-stage heart failure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need.

Transplant 40

Transplant Heart Transplant Heart Dysfunction Heart Failure 40

DAIC

MAY 15, 2024

milla1cf Wed, 05/15/2024 - 08:50 May 15, 2024 — The U.S. 882 Dates Distributed: March 1, 2021 to present Date Initiated by Firm: March 13, 2024 Device Use The HeartMate 3 Left Ventricular Assist System (LVAS) is used to help the heart pump blood when it is not able to do so effectively on its own.

Transplant 105

Transplant Heart Failure Heart Transplant Pediatrics 105

DAIC

APRIL 15, 2024

Image courtesy of Abbott mtaschetta-millane Mon, 04/15/2024 - 09:54 April 15, 2024 — The U.S. This occurs when biological material builds up between certain parts of the device, causing a blockage that makes it harder for the heart to pump blood. Food and Drug Administration ( FDA ) announced A bbott/Thoratec Corp.

Transplant 105

Transplant Heart Transplant Pediatrics Heart Failure 105

DAIC

MARCH 13, 2024

Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , The CMS coverage approval is supported by the scientific rigor of the protocol design and the results from the interim data from the CardiAMP Heart Failure Trial recently presented at the Technology and Heart Failure Therapeutics 2024 annual meeting.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

The American Journal of Cardiology

JULY 6, 2024

Publication date: Available online 6 July 2024 Source: The American Journal of Cardiology Author(s): Jacob Agronin, Meredith Brown, Hannah Calvelli, Huaqing Zhao, Val Rakita, Yoshiya Toyoda, Mohammed Abul Kashem

Heart Transplant 40

Heart Transplant Transplant Outcomes 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146920-A4146920, November 12, 2024. Cox regression results showed that there is an increased risk of mortality in patients who did not receive transfusions before transplant (p<0.0001).Conclusion:While

Transplant 40

Transplant Heart Transplant Risk Factors Outcomes 40

The British Journal of Cardiology

DECEMBER 3, 2024

A 74-year-old man with a heterotopic heart transplant experienced alternating episodes of sustained native heart ventricular tachycardia and prolonged asystole. These were managed with cardioversion, drug therapy and pacemaker insertion.

Heart Transplant 40

Heart Transplant Transplant Pacemaker Physiology 40

Cardiology Update

APRIL 9, 2024

The American College of Cardiology (ACC) held its 73 rd annual scientific session and expo April 6-8, 2024 in Atlanta, Georgia. Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). April 6, 2024. April 7, 2024. April 7, 2024.

Myocardial Infarction 52

Myocardial Infarction Angina Aortic valve Coronary Artery Disease 52

HeartRhythm

FEBRUARY 29, 2024

In the editorial commentary titled “Is more, “more” when itcomes to pacing in heart transplant patients?” Rod Gimbel published in February 2024 (2024;21;161-162) in Heart Rhythm, the surname of the related article’s first author, Zain Gowani, is incorrectly referred to as Gowali. The author regrets this error.

Heart Transplant 40

Heart Transplant Heart Rhythm Transplant 40

European Journal of Heart Failure

DECEMBER 1, 2024

The primary endpoint was survival at 180 days and freedom from implantable cardioverter-defibrillator (ICD), heart transplant/left ventricular assist device (LVAD), or readmission for heart failure. Functional status was assessed with New York Heart Association (NYHA) classification.

Cardiogenic Shock 40

Cardiogenic Shock Heart Transplant Outcomes Transplant 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4113494-A4113494, November 12, 2024. End-stage ischemic heart disease necessitates heart transplantation, and emerging cell therapy presents a promising solution to address donor scarcity.

Ischemia 40

Ischemia Transplant Heart Transplant Biomarkers 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4146823-A4146823, November 12, 2024. Heart transplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Patients without CHD were older (mean age 71.5

Cardiogenic Shock 40

Cardiogenic Shock Congenital Heart Disease Heart Failure Congenital 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4134590-A4134590, November 12, 2024. The association between a lower rate of MAE and EMB persisted in the multivariate model when those with heart transplant who had EMB were compared to those without heart transplant who did not have EMB p=0.001.

Cardiomyopathy 40

Cardiomyopathy Pediatrics Heart Transplant Heart Failure 40

All About Cardiovascular System and Disorders

FEBRUARY 24, 2024

Heart failure, heart transplantation and death by cardiac causes were more often seen in individuals with biventricular phenotype compared to isolated left or right ventricular phenotype. 2024 Feb 27;83(8):797-807. Phenotypic Expression and Clinical Outcomes in Patients With Arrhythmogenic Cardiomyopathies. 2023.12.015.

Cardiomyopathy 52

Cardiomyopathy Chest Pain Heart Transplant Myocardial Infarction 52

DAIC

APRIL 6, 2024

24, in Atlanta, GA. Researchers tracked outcomes in each participant for at least one year and up to two years.

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81

DAIC

APRIL 6, 2024

Stone will present the study, “A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients with HfrEF and HfpEF: Principal Results from the RELIEVE-HF Trial,” on Saturday, April 6, 2024, at 9:30 a.m. Researchers tracked outcomes in each participant for at least one year and up to two years.

Heart Failure 75

Heart Failure Quality of Life Preserved Ejection Fraction Hospital 75

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4144326-A4144326, November 12, 2024. It has changed the fate of young patients with large tumors who would have otherwise needed heart transplants, offering high suture strength and reducing postoperative complications. During a median follow-up period of 17.4

Pediatrics 40

Pediatrics Outcomes Heart Transplant Aneurysm 40

DAIC

APRIL 8, 2024

milla1cf Mon, 04/08/2024 - 18:07 April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology ’s Annual Scientific Session.

Heart Attack 52

Heart Attack Heart attacks Cardiogenic Shock Catheterization Laboratory 52

DAIC

MARCH 6, 2024

Food and Drug Adminstration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly. 5 Kutty, S., et al (2016).

Pediatrics 105

Pediatrics Ultrasound Heart Transplant Echocardiogram 105

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4139383-A4139383, November 12, 2024. Background:Immunosuppressive (IS) therapy is currently used as first-line treatment for heart transplant (HTx) rejection. However, they are not without complications, and less toxic therapies are needed. years, males: 58.4%).

Heart Transplant 40

Heart Transplant Transplant Cardiovascular Disease Outcomes 40

DAIC

MARCH 29, 2024

milla1cf Fri, 03/29/2024 - 08:08 March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology 's ( ACC ) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Quality of Life Hospital 111

DAIC

JUNE 24, 2024

milla1cf Mon, 06/24/2024 - 20:21 June 24, 2024 — Endotronix, Inc. , a privately held company dedicated to advancing the treatment of heart failure ( HF ) at the intersection of digital health and medtech, today announced Premarket Approval (PMA) from the U.S

Heart Failure 109

Heart Failure Reimbursement Heart Transplant Pulmonary 109

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4138589-A4138589, November 12, 2024. All patients were prospectively followed for development of new outcome/cardiac events which included hospitalization for acute HF, CVS-related death, heart transplantation, and also diabetic complications.

Coronary Artery Disease 40

Coronary Artery Disease Diabetes Heart Transplant Tricuspid 40

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52